Comparative Pharmacology
Head-to-head clinical analysis: SUFLAVE versus TRILYTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUFLAVE versus TRILYTE.
SUFLAVE vs TRILYTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SUFLAVE is a combination of sulfamethoxazole, a sulfonamide antibiotic, and trimethoprim, a dihydrofolate reductase inhibitor. It inhibits bacterial folic acid synthesis by blocking two consecutive steps: sulfamethoxazole competes with PABA to inhibit dihydropteroate synthase, and trimethoprim inhibits dihydrofolate reductase, leading to bactericidal activity.
TRILYTE (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, ascorbic acid) is an osmotic laxative. The active components induce diarrhea by osmotically drawing water into the gastrointestinal lumen, thereby increasing stool volume and stimulating peristalsis. Sodium ascorbate and ascorbic acid enhance the osmotic effect.
250 mg intravenously every 12 hours.
Adults: 1 liter (L) orally every 10-15 minutes until 4 L total consumed; complete ingestion within 4 hours.
None Documented
None Documented
Terminal elimination half-life: 3.5 hours (range 2.5–4.5 h) in healthy adults; prolonged in renal impairment (up to 10 h in anuria)
Not applicable; non-absorbed, acts locally in GI tract
Renal: 70% unchanged; fecal/biliary: 20%; 10% metabolized to inactive glucuronide
Renal excretion of intact electrolyte ions; negligible drug excretion
Category C
Category C
Laxative
Laxative